Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
Crystalline salts of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine, compositions thereof, methods for their preparation, and methods for their use are disclosed.
1. A crystalline salt of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine selected from the group consisting of:
besylate salt, which has substantially the same X-ray power diffraction (XRPD) pattern as shown in FIG. 15 ;
camsylate salt, which has substantially the same X-ray power diffraction (XRPD) pattern as shown in FIG. 16 ;
esylate salt, which has substantially the same X-ray power diffraction (XRPD) pattern as shown in FIG. 17 ;
HBr salt, which has substantially the same X-ray power diffraction (XRPD) pattern as shown in FIG. 18 ;
sulfate salt, which has substantially the same X-ray power diffraction (XRPD) pattern as shown in FIG. 20 ;
tosylate salt, which has substantially the same X-ray power diffraction (XRPD) pattern as shown in FIG. 21 ; and
HCl salt, which has substantially the same X-ray power diffraction (XRPD) pattern as shown in FIG. 22 .
2. A crystalline HCl salt of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine having substantially the same XRPD pattern as shown in FIG. 22 .
3. A crystalline HCl salt of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine that is a polymorph (Form I) having a XRPD pattern comprising peaks at degrees 2-theta diffraction angles of about 8.8, 10.8, 16.1, 17.4, 20.4, 20.9, 21.5, 21.7, 26.6, and 28.1.
4. The polymorph of claim 3 having substantially the same XRPD pattern as shown in FIG. 1 .
5. The polymorph of claim 3 having a DSC thermogram comprising an endotherm onset at about 191° C.
6. The polymorph of claim 3 having a DSC thermogram substantially as shown in FIG. 2 .
7. The polymorph of claim 3 having a Raman spectrum substantially as shown in FIG. 4 .
8. A crystalline HCl salt of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine that is a polymorph (Form II) having a XRPD pattern comprising peaks at degrees 2-theta diffraction angles of about 7.8, 10.1, 12.5, 18.4, 19.0, 20.8, 23.0, and 23.5.
9. The polymorph of claim 8 having substantially the same XRPD pattern as shown in FIG. 5 .
10. The polymorph of claim 8 having a DSC thermogram comprising an endotherm onset at about 150° C.
11. The polymorph of claim 8 having a DSC thermogram substantially as shown in FIG. 6 .
12. A pharmaceutical composition comprising the crystalline salt of claim 1 .